Target Looming: NHS Falls Short of 80% Treatment Goal
The NHS England is on course to miss its pivotal cancer‑treatment benchmark by roughly ten thousand patients, according to a fresh analysis of official figures. The interim objective – to ensure that 80 % of cancer patients begin treatment within 62 days of urgent referral or consultant upgrade by March 2027 – is slipping away. In September the on‑time treatment rate stood at 70.7 %, down from 71.9 % the previous month, and with just over 100 days remaining the trajectory points toward a systematic shortfall.
The charity Radiotherapy UK calculates that, to close the gap, the service would need to bring an extra 2 850 patients into the treatment stream each month, assuming patient volumes stay steady. To achieve the 80 % mark, roughly 24 400 cancer patients per month would have to start therapy on schedule, yet the NHS is currently managing only about 21 500. This monthly deficit of 2 850 patients accumulates to a near‑ten‑thousand‑patient shortfall, a gap that experts say could have life‑or‑death implications.
Monthly Shortfall and Cumulative Gap
The arithmetic is stark. At present, the health service treats just over 21 500 cancer patients within the 62‑day window each month. To meet the March 2027 target, that figure must rise to 24 400. The difference – 2 850 extra patients per month – is the exact amount the NHS must absorb to stay on track. Over a year, that translates into roughly 34 200 additional treatments, a scale that many within the system say is beyond current capacity.

The cumulative impact is equally sobering. The charity’s modelling shows a shortfall of 9 490 patients to date, with the final tally likely to exceed 10 000 by the deadline. This shortfall is not a theoretical exercise; it represents real individuals whose treatment is being delayed, often beyond the window that offers the best chance of cure.
Uneven Care: Cancer Type and Regional Disparities
Disparities in timely treatment are pronounced across tumour types. Prostate and breast‑cancer patients enjoy relatively high on‑time rates – 70.1 % and 68.8 % respectively – pushing them above the two‑thirds benchmark. By contrast, lung‑cancer sufferers are treated promptly in only 60.9 % of cases, while gynaecological cancers lag at 60 %. Head‑and‑neck malignancies fare worst, with just 56.5 % receiving treatment within the target period.
Geography compounds the problem. The Midlands records the lowest on‑time treatment proportion at 66.6 %, whereas London manages 77.3 %. This regional imbalance underscores a broader systemic fracture, where some centres thrive while others struggle to meet even basic standards.
Voices from the Frontlines: Experts Sound the Alarm
Prof Pat Price, chair of Radiotherapy UK and a leading oncologist, warned that “the government is going to miss its cancer treatment target because the NHS does not have enough staff or equipment to treat the number of patients coming through its doors. This lack of leadership means thousands more people could die because they don’t get their treatment on time.”

Mark Lawler, professor of digital health and translational cancer genomics at Queen’s University Belfast, described the system as “held together by goodwill glue alone. Lack of leadership is derailing efforts to improve cancer survival. Unless there is accountability for these failures by the NHS, a radical change in mindset and a focus on the basics, we will miss hitting treatment targets for another decade.”
Naser Turabi, Cancer Research UK’s director of health policy and evidence, highlighted a capacity crunch: “Hospital capacity is not able to keep pace with surging demand for cancer diagnosis – with urgent referrals in England up about 20 % over the past four years alone. While recent investment in diagnostic equipment is welcome, we’re not seeing enough progress to cut waiting times for the 6 % of people who go on to receive a cancer diagnosis.”
Dr Hilary Williams, the Royal College of Physicians’ clinical vice‑president and a consultant oncologist, stressed that “crucial earlier diagnosis was only beneficial if patients could then be treated quickly. To close the gap, the NHS needs sufficient capacity across the whole cancer pathway – more diagnostic capacity, including imaging, endoscopy and pathology, alongside the specialist workforce needed to deliver and interpret those tests. It also means enough treatment capacity in surgery, radiotherapy and systemic treatments so that diagnosing people more quickly doesn’t simply move the bottleneck further down the pathway.”
Dr Stephen Harden, president of the Royal College of Radiologists, pointed to staffing shortages: “Chronic shortages” of clinical radiologists and oncologists, who diagnose, monitor and treat cancer, were “driving dangerous delays” in care. “Perversely, NHS hiring freezes for these doctors have doubled in the last year, making it even harder to keep patients safe,” he added. “Technology and new ways of working can relieve pressure to an extent, but fundamentally, rising demand for cancer care has outpaced workforce capacity. The government must now step in to end recruitment freezes and ensure services have the doctors they need to diagnose and treat patients on time.”
A Department of Health and Social Care spokesperson offered a counterpoint: “Cancer waiting times are moving in the right direction, with all three cancer standards better than a year ago, and around 290 000 more people over the last year getting diagnosed on time or having cancer ruled out, compared to the year before the election. But we know there is much more to do. Our national cancer plan will help more people to get diagnosed earlier and begin treatment sooner, giving them the best possible chances of recovery and survival.”
Why it Matters
The looming failure to meet the 80 % 62‑day treatment target is not merely a statistical blip; it represents a systemic breakdown that threatens thousands of lives across England. The widening gap between diagnosis and treatment, coupled with stark regional and tumour‑type disparities, reveals a health service stretched beyond its current staffing and equipment limits. Unless decisive action is taken – from ending recruitment freezes and bolstering diagnostic capacity to restoring accountable leadership across the NHS – the consequences will extend far beyond missed figures, manifesting as delayed cures, reduced survival rates, and an erosion of public confidence in one of the nation’s most vital institutions.
